Prevalence of cerebral venous thrombosis with the use of oral contraceptive pills during the Holy month of Ramadan

Authors

• Mohammed AlSheef, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Mastourah Alotaibi, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Areej Alshamrani, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Aroub Alhamidi, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Noor Alanazi, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Sarah Alhathlool, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Ohoud Alarfaj, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Mohammed AlHazzaa, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Ghaydaa Kullab, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Amany Alboghdadly, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia
• Amani Abu-Shaheen, From the Department of Medicine (AlSheef, Zaidi A, Kullab), from Department of Adult Hematology/BMT (Zaidi S), from the Department of Clinical Pharmacy (Alarfaj), from the National Neuroscience Institute (AlHazzaa), from the Research Center (Abu-Shaheen), King Fahad Medical City; and from the College of Pharmacy (Alotaibi, Alshamrani, Alhamidi, Alanazi, Alhathlool, Alboghdadly), Princess Nourah Bint Abdulrahman University, Riyadh, Kingdom of Saudi Arabia

Abstract

Objectives: To identify the epidemiologic profile of cerebral vein thrombosis (CVT) among fasting women using oral contraceptive pills (OCPs) during the holy month of Ramadan. Methods: This retrospective study was conducted on all patients diagnosed with CVT and using OCPs from records at a tertiary care hospital in Riyadh, Saudi Arabia during 2016-2017. The study participants were categorized into 2 groups (an intermittently fasting group during the holy month of Ramadan and a non-fasting group). Results: Out of 108 female patients with CVT, 36.1% were secondary to OCP, of whom 41% participants were fasting. The most affected site was the transverse sinus. Holocephalic headache was more common amongst fasting group (68.8%) compared to non-fasting group (30.4%) ( p =0.025). Dehydration ( p =0.003) amongst the fasting group and protein S deficiency ( p =0.027) in the non-fasting group were identified as the 2 prominent risk factors. Unfractionated heparin was the most common anticoagulant therapies used during the initiation phase for non-fasting (36.4%) and fasting groups (50%). Conclusion: All women who are using OCP should undergo formal written risk assessments for factors of CVT. Our study suggests that the negative effects of OCPs use might outweigh its benefits; thus, it should be prescribed with caution, more so in fasting patients.

Article Type

Research Article

First Page

1063

Last Page

1069

Recommended Citation

AlSheef, Mohammed; Alotaibi, Mastourah; Alshamrani, Areej; Alhamidi, Aroub; Alanazi, Noor; Alhathlool, Sarah; Alarfaj, Ohoud; AlHazzaa, Mohammed; Kullab, Ghaydaa; Alboghdadly, Amany; and Abu-Shaheen, Amani (2020) "Prevalence of cerebral venous thrombosis with the use of oral contraceptive pills during the Holy month of Ramadan," Saudi Medical Journal: Vol. 41: Iss. 10, Article 5.
DOI: https://doi.org/10.15537/smj.2020.10.25397